Funding Opportunity PAR-22-083 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Funding Opportunity RFA-ES-22-002 from the NIH Guide for Grants and Contracts. The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their independent environmental health sciences research program.

Funding Opportunity RFA-HD-22-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy-related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.

Funding Opportunity PAR-22-102 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and Small Disadvantaged small business are encouraged to apply.

Funding Opportunity PAR-22-103 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and Small Disadvantaged small business are encouraged to apply.

Competitive Salary: Rothamsted Research: KnetMiner (https://knetminer.com) is an innovative gene discovery and analytics platform using Knowledge Graphs... Harpenden

EUR 3.945,90 (following the recommendations of FWF): CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: We are seeking an enthusiastic and energetic candidate for a Data Scientist in Metabolomics position to...... Vienna (AT)

Competitive Salary: EMBL: The Open Targets (OT) project aims to systematically identify and prioritise drug targets by combining genetic, clinical and functional genomics data. Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: Are you creative, curious, and ambitious and like to tackle challenging biological data analysis problems? We have an exciting opportunity for a bio Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: ELIXIR is seeking an experienced bioinformatician who can combine technical understanding of current trends in bioinformatics software (development an Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: Ensembl is a leading genome informatics resource, one of the most highly used by scientists across the world. In the Variation team, we integrate and Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: We are looking for an experienced and energetic Senior Digital Product Designer to join EMBL’s European Bioinformatics Institute (EMBL-EBI) in our mis Hinxton, Cambridgeshire, England

Funding Opportunity RFA-HL-23-001 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to understand the heterogeneity and underlying mechanisms of critical illness syndromes and recovery in adults. This will be accomplished by a longitudinal observational study with common data and biospecimen collection of hospitalized adults with ARDS, community-acquired pneumonia, or sepsis from hospitalization to 1 year.

Funding Opportunity RFA-HL-23-002 from the NIH Guide for Grants and Contracts. This funding opportunity annoucement (FOA) seeks applications for a Coordinating Center that will support the activities of a cooperative multi-siteAcute Respiratory Distress Syndrome (ARDS),Pneumonia, andSepsis Phenotyping Consortium (APS Consortium). The APS Consortium will seek to understand the heterogeneity and underlying mechanisms of critical illness syndromes and recovery, specifically in adults with ARDS, pneumonia, and/or sepsis, as well as the relationship and biological overlap among these syndromes. This will be accomplished through a prospective, longitudinal observational study with common data and biospecimen collection of 5,000 hospitalized adults with one or more of the following diagnoses: ARDS, pneumonia, or sepsis. It is expected that approximately half of the participants discharged from the hospital will have follow-up at 3, 6, and 12 months to facilitate understanding of long-term outcomes, including biological and physiological resolution of ARDS, pneumonia, and sepsis. Throughout the programs funding period, data (including imaging data) and biospecimens collected will be made available as a resource to the broader research community as rapidly and simply as possible.

Funding Opportunity RFA-DK-22-005 from the NIH Guide for Grants and Contracts. The impact of pain on patient quality of life for diseases and conditions within the mission of the NIDDK is enormous. Despite prior research efforts, our understanding of the underlying biological and clinical contributors of pain remains limited. In addition, new clinical management strategies that better measure, predict, and target pain and improve upon current interventions, such as opioids, are critically needed. The current Funding Opportunity Announcement will address these needs through solicitation of broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK's mission. Investigations are expected to provide important new insights into the pathophysiology and clinical features of pain and foster new and improved treatment and pain management strategies for patients.

Funding Opportunity RFA-DE-22-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is soliciting applications to support the analysis of existing data and resources from humans, including large, diverse national research cohorts, to answer specific questions about the development of human acute or chronic pain and its management. Applications may be related to, but must be distinct from, the specific aims of the original data collection. Generation of new primary data with this funding is not allowed.

Funding Opportunity RFA-MH-22-175 from the NIH Guide for Grants and Contracts. As part of NIHs Helping to End Addiction Long Term (HEAL) Initiative, this RFA invites research that will optimize multi-component service delivery interventions for people with opioid use disorder and co-occurring conditions, to include suicide risk. The purpose of the initiative is to support studies that will test (1) overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. Studies are to be highly pragmatic and practice relevant, with designs that balance rigor with time-to-practice urgency. Projects will seek to a) identify constitute components that drive improvements in access, continuity, quality, value, and outcomes of care, for service delivery interventions with previously demonstrated effectiveness as a bundled package; and b) simultaneously test overall effectiveness of the package and its subcomponents, for popular (widely implemented) service delivery packages without previously demonstrated effectiveness.

Funding Opportunity RFA-MH-22-176 from the NIH Guide for Grants and Contracts. As part of NIHs Helping to End Addiction Long Term (HEAL) Initiative, this RFA invites research that will optimize multi-component service delivery interventions for people with opioid use disorder and co-occurring conditions, to include suicide risk. The purpose of the initiative is to support studies that will test (1) overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. Studies are to be highly pragmatic and practice relevant, with designs that balance rigor with time-to-practice urgency. Projects will seek to a) identify constitute components that drive improvements in access, continuity, quality, value, and outcomes of care, for service delivery interventions with previously demonstrated effectiveness as a bundled package; and b) simultaneously test overall effectiveness of the package and its subcomponents, for popular (widely implemented) service delivery packages without previously demonstrated effectiveness.

Notice NOT-TR-22-015 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-22-145 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-20-128 This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will cover the way that all of those groups are collecting data. The developed standard is expected to be made widely available.